Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9312934 | 0.79 | RAB9A (0.58) | RAB9ANPC1POLBHPGDNPSR1 | |
| SCHEMBL16830166 | 0.79 | BRD4 (0.44) | PKM | |
| SCHEMBL20268574 | 0.77 | BRD4 (0.44) | PKM | |
| SCHEMBL16830216 | 0.75 | BRD4 (0.42) | HPGDKMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL16830301 | 0.74 | BRD4 (0.41) | PKM | |
| SCHEMBL16849945 | 0.74 | PDK2 (0.40) | — | |
| SCHEMBL16849948 | 0.73 | PDK2 (0.36) | MAPTALDH1A1 | |
| SCHEMBL16830164 | 0.73 | BRD4 (0.46) | — | |
| SCHEMBL16830193 | 0.72 | PDK2 (0.33) | KMT2A | |
| SCHEMBL9196711 | 0.72 | GRIK1 (0.55) | RAB9ANPC1POLBHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336697-B2 | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2019-07-02 | — | — | US | claimed |
| US-20180186739-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2018-07-05 | — | — | US | claimed |
| US-10336697-B2 | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2019-07-02 | — | — | US | disclosed |
| US-10336697-B2 | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2019-07-02 | — | — | US | disclosed |
| US-20180186739-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2018-07-05 | — | — | US | disclosed |
| US-20180186739-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2018-07-05 | — | — | US | disclosed |
| EP-3310772-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | Orion Corporation (FI) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016203112-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016203112-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336697-B2 | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors | BRD4, BRD3, BRD1 | RAB9A 3437/4885NPC1 2586/4885POLB 1085/4885 |
| US-20180186739-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | RAB9A 3473/4885NPC1 2620/4885POLB 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.